Allarity Therapeutics enters $947,000 at-the-market equity offering agreement with Ascendiant Capital

Allarity Therapeutics, Inc.

Company entered ATM sales agreement with Ascendiant Capital for up to $947,000 of common stock.
Agent commission 3.0% of gross proceeds; expenses reimbursement up to $30,000.
Sales may be made on Nasdaq at market prices; agreement effective until March 2026 or earlier termination.
Placement Shares subject to General Instruction I.B.6 limitations until public float exceeds $75M.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Allarity Therapeutics, Inc. entered into At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $947,000 (effective 2024-03-19).

Action: entry
Agreement: atm program
Counterparty: Ascendiant Capital Markets, LLC
Value: up to $947,000
Effective: 2024-03-19

Exact text from the filing

On March 19, 2024, Allarity Therapeutics, Inc. (the “ Company ”), entered into an At-The-Market Issuance Sales Agreement (the “ Agreement ”) with Ascendiant Capital Markets, LLC (the “ Agent ”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares

View on SEC.gov

Browse all material agreements →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-024156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.